Introduction
cartilage [12, 13] 
. In view of the importance of SOX-9 in the development and maintenance of chondrocytes phenotype, its downregulation in OA is clearly likely to contribute to cartilage pathology.
Changes in chondrocyte behaviour, including matrix remodelling, proliferation and apoptosis, are associated with OA progression and these behaviours are characteristic of chondrocyte maturation and hypertrophy in developing growth plates [14] [15] [16] . When chondrocytes acquire a hypertrophic osteoarthritic phenotype, they start to express Col10a1 and not Col2a1 [3] . Runt-related transcription factor 2 (RUNX-2), which was originally isolated for its ability to activate transcription of the osteoblast-specific osteocalcin gene [17] [18] , is known to induce chondrocyte hypertrophy [19] [20] [21] . Additionally several other transcription factors, such as Shox/Shox2, Dlx5, MEF2C, have been identified as positive or negative regulators of chondrocyte hypertrophy in mouse models [22] [23] [24] [25] . Overexpression of RUNX-2 in chondrocytes promotes collagen type X and alkaline phosphatase expression, which are both up-regulated in OA cartilage [26] [27] [28] [29] . As RUNX-2 activity is a key determinant of chondrocyte maturation in the growth plate and experimentally in permanent cartilage, it might as well be a focal point of the abnormal signalling mechanisms that promote the initiation and progression of OA [30] . Recent [31] . [32, 33] [34] . FGF-23 acts as a negative regulator of chondrogenesis and may induce premature exit of proliferating chondrocytes into hypertrophy leading to shorter bone growth [35] . Recently it was shown that FGF-23 is localized in the hypertrophic chondrocytes and may play a role in chondrocyte maturation [36] . Moreover, in phosphorus-loaded rats overexpression of FGF-23 resulted in smaller growth plate with significant reduction in chondrocyte proliferation, which was maintained by down-regulating the transcription factor RUNX-2 [37] [38] [39] .
studies have shown that SOX-9 acts as a transcriptional repressor for osteoblasts differentiation and chondrocyte hypertrophy partly via inhibition of RUNX-2 transactivation

Furthermore, it has been shown that FGF signalling up-regulates RUNX-2 expression and activity in osteoblasts
. FGF-23 is a novel member of the FGF family and is an important regulator of serum phosphorus, which is essential in chondrocyte differentiation and mineralization
In order to advance our understanding regarding the pathways involved in the catabolic and degenerative processes in osteoarthritic articular cartilage, we investigated the possible associations among RUNX-2, FGF-23 and SOX-9 in osteoarthritic cartilage. Fig. 2A) . Moreover, both siRNAs inhibited RUNX-2 protein expression in similar levels (Fig. 2B) .
Materials and methods
Patients and cartilage tissue samples
We (Fig. 2D) .
Fig. 1 Quantitative RUNX-2 mRNA expression (A) freshly isolated (P Ͻ 0.0001) and (B) cultured normal and osteoarthritic chondrocytes (P Ͻ 0.0001).
Fig. 2 (A) RUNX-2 inhibition with siRNA1 and siRNA2 (B) RUNX-2 protein expression after 48 hrs siRNA1 and siRNA2 transfection (C) MMP-13 mRNA expression 0, 24, 36 and 48 hrs after RUNX-2 inhibition (P Ͻ 0.0001) (D) Assessment of MMP-13 expression by immunofluorescence after 48 hrs of RUNX-2 inhibition with two different siRNAs. All experiments were performed in OA chondrocytes. (A) and (B) were normalized to GAPDH. siRNA-scrambled was used as a control.
Association between SOX-9 mRNA expression, RUNX-2 and MMP-13 expression
SOX-9 mRNA expression levels were evaluated in osteoarthritic and normal chondrocytes from freshly isolated ex vivo cartilage by real-time PCR. SOX-9 was highly down-regulated in osteoarthritic chondrocytes and was highly expressed in normal chondrocytes
(P Ͻ 0.0001) (Fig. 3A) . (Fig. 3B) .
Using real-time PCR we determined the relative expression levels of both SOX-9 and RUNX-2, which were normalized to the same reference gene, GAPDH and calculated the ratio of RUNX-2 to SOX-9 transcripts (RUNX-2/SOX-9). Our results demonstrate that the ratio RUNX-2/SOX-9 increases in osteoarthritic and decreases in normal cartilage (P Ͻ 0.0001)
Subsequently, SOX-9 mRNA expression levels were blocked with two different siRNAs in normal chondrocytes and we confirmed its silencing by evaluating its protein levels (Fig. 4A) .
We then tested RUNX-2 mRNA expression after silencing of SOX-9 by siRNA in normal chondrocytes. Our results showed that inhibition of SOX-9 mRNA expression by transfection with siRNA1 and siRNA2 against SOX-9 affects RUNX-2 mRNA expression leading to its up-regulation compared to the untransfected and the siRNA-scrambled 48 hrs after siRNA1 and siRNA2 transfection. Subsequently, it seems that SOX-9 mRNA expression is associated with reduced or absence of RUNX-2 mRNA expression in normal chondrocytes (Fig. 4B) . (Fig. 4C) . (Fig. 5A P Ͻ 0.0001, Fig. 5B) .
Considering that RUNX-2 expression is associated with increased MMP-13 expression, we proceeded to test, MMP-13 expression levels after inhibiting SOX-9 mRNA expression. Our results revealed that inhibition of SOX-9 expression with two different siRNAs, resulted in up-regulation of MMP-13 mRNA expression in normal chondrocytes
Association between FGF-23 mRNA expression and RUNX-2 expression
We determined FGF-23 mRNA and protein expression in normal and osteoarthritic cartilage by real-time PCR and Western blotting, respectively. Our results indicated that FGF-23 is highly up-regulated in osteoarthritic cartilage and has low expression levels in normal cartilage
We next investigated whether the addition or inhibition of FGF-23 could modulate RUNX-2 expression. Normal chondrocytes were treated with different concentrations of hrFGF-23 for 2 days and subsequently RUNX-2 mRNA expression was determined.
We found that hrFGF-23 increases RUNX-2 mRNA levels in a dose-dependent manner (20, 50 , 100 ng/ml) in normal chondrocytes and the maximum increase of RUNX-2 mRNA expression was observed after 100 ng/ml treatment with hrFGF-23 (Fig. 5C) . (Fig. 5D ). (Fig. 5E) . The 5.5-fold difference in RUNX-2 induction between hrFGF-23 and siRNA-SOX-9 stimuli does not suggest that these two proteins act in the same pathway. (Fig. 6 ).
Moreover, we checked RUNX-2 expression after FGF-23 inhibition with siRNA against FGF-23 in OA chondrocytes (48 hrs after transfection). We found that inhibition of FGF-23 blocked more than 80% of RUNX-2 mRNA expression in OA chondrocytes compared to a negative control
FGF-23 and SOX-9 activate RUNX-2 expression in normal chondrocytes
In order to identify if FGF-23 regulates SOX-9, we treated normal chondrocytes with hrFGF-23 (100 ng/ml) and tested SOX-9 protein expression (Fig. 5F). We did not find any changes in SOX-9 levels suggesting that FGF-23 does not regulate SOX-9 expression. Moreover inhibition of FGF-23 or RUNX-2 in osteoarthritic chondrocytes by siRNA did not affect SOX-9 mRNA levels (data not shown). These findings suggest that SOX-9 is a suppressor, whereas FGF-23 is an activator of RUNX-2 expression in chondrocytes
Discussion
The 
